Written answer
Health Screening Programmes
The Minister said HIQA is conducting a Health Technology Assessment on expanding BreastCheck to ages 45–49 and 70–74 and introducing standardised breast-density notification. Decisions will follow evidence-based NSAC recommendations; costs cannot be estimated until the assessment is complete.
379. Deputy Marie Sherlock asked the Minister for Health the consideration her Department has given to targeted, risk stratified cancer screening for breast cancer for persons under the age 50. [66185/26]
Comment on this
385. Deputy Marie Sherlock asked the Minister for Health the cost, if any, of imparting breast density information in each mammogram or breast scan. [66178/26]
Comment on this
I propose to take Questions Nos. 379 and 385 together.
As Minister for Health, I am committed to supporting our population screening programmes, which are a valuable part of our health service, enabling early treatment and care for many people, and improving the overall health of our population.
The Programme for Government commits to extending the BreastCheck Screening Programme, in line with updated standards from HIQA.
BreastCheck, the national breast cancer screening programme, currently invites women aged 50 to 69 years at regular periods to have a routine mammogram. Under commitments in the Programme for Government, BreastCheck eligibility has been expanded to women aged 69 years since 2021.
In Budget 2026, 20 (WTE) positions were allocated to National Screening Services, of which 10 were assigned to BreastCheck. In 2025, an additional €2.9 million was allocated to the BreastCheck programme to support the recruitment of 22 Whole Time Equivalent (WTE) posts, with an additional 15 WTE posts approved. This will assist in expanding and future-proofing the programme to meet increased demand.
I would note that any proposed changes to Ireland’s cancer screening programmes, will be facilitated through established evidence-driven protocols. The National Screening Advisory Committee (NSAC) is the independent expert group that considers proposed changes to Ireland’s screening programmes. NSAC assesses the evidence in a robust and transparent manner and against internationally accepted criteria, before making recommendations to myself as Minister.
At the request of NSAC, the Health Information and Quality Authority (HIQA) has commenced a Health Technology Assessment (HTA) to consider proposals for the expansion of the BreastCheck programme. This review will comprise two elements; the proposed extension of the age range eligibility to those aged 45-49 and 70-74, and also the potential introduction of a standardised breast density notification.
HTAs facilitate the assessment of relevant evidence and knowledge on the effects and consequences of healthcare technologies to guide decisions regarding the appropriate use of technology and efficient allocation of resources. They involve a multi-disciplinary assessment of the clinical, economic, ethical, legal and societal perspectives that may be impacted by the introduction of a new technology.
HTAs are time intensive and rigorous processes that must be afforded the necessary amount of time?to complete. This is particularly relevant in the context of the BreastCheck HTA, which is considering three distinct areas, the potential to increase the age eligibility, to decrease the age eligibility and potential reporting of breast density.
An estimated cost for extending the BreastCheck programme cannot be provided until the final HIQA HTA report has been published.
Finally, I would like to emphasise that population-based screening programmes are for people without symptoms. If anyone becomes aware of symptoms, or if they have concerns or worries, they should contact a medical professional.